Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAducanumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Aducanumab
- Accession Number
- DB12274
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Aducanumab has been used in trials studying the treatment of Alzheimer's Disease.
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Aducanumab
- External IDs
- BIIB 037 / BIIB-037 / BIIB037
- Categories
- UNII
- 105J35OE21
- CAS number
- 1384260-65-4
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Aducanumab. Abituzumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Abituzumab. Abrilumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Abrilumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Aducanumab. Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Aducanumab. Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Aducanumab. Amatuximab The risk or severity of adverse effects can be increased when Aducanumab is combined with Amatuximab. AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Aducanumab. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911309
- Wikipedia
- Aducanumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Basic Science Alzheimer's Disease (AD) 1 1 Completed Treatment Alzheimer's Disease (AD) 2 1 Terminated Treatment Alzheimer's Disease (AD) 1 2 Terminated Treatment Alzheimer's Disease (AD) / Cognitive Dysfunctions 1 3 Enrolling by Invitation Treatment Alzheimer's Disease (AD) 1 3 Terminated Treatment Alzheimer's Disease (AD) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Drug created on October 20, 2016 15:47 / Updated on March 01, 2020 21:09
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"Clinical-1.jpg":"/assets/ads/Clinical-1-0efffcd68b99e28deae3611717239df1f86dcd50500066e39a7c19d08f91988b.jpg","Drug-Search-2.jpg":"/assets/ads/Drug-Search-2-2f3603461a3ccebb5cf2387e5b24146852d1952a198725dfb72abd325bf1d4a9.jpg","DDI-2.jpg":"/assets/ads/DDI-2-0b012e4822a96439344683dad971ca9f896e601daf48ee0d8932e45e6a3036a2.jpg","CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-a30b86c438f5468a993dfa1b02728b4c9b8c406771ab717321f242913f105eae.jpg","Covid.jpg":"/assets/ads/Covid-b36ff36fa999f6e848e56a47b413deb0d6327c37ec1860a961e18153c8841d1c.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-126f59819adfcc111994629f2e55bdec8802bd17f9268e5ed4931222d586f88f.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-b939cf2cc5f6c8d114a532430ca265ecec02ddf02a50c9302912da5e477097a7.jpg","PM-3.jpg":"/assets/ads/PM-3-f1ca930890153399424501785b8c386b545ed612b7c88b6513e11d90b920e110.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates